Is there underinvestment in R and D about prevention?

Journal of Health Economics

Volumn 17, Issue 1, 1998, Pages 117-127

  Dranove, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL;

COST BENEFIT ANALYSIS; FINANCE; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; INVESTMENT; LAW SUIT; MANAGED CARE; MEDICAL RESEARCH; NOTE; PREVENTION;

EID: 0031961822     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-6296(97)00015-5     Document Type: Article

References (9)

1. DiMasi, J. et al., 1991. The cost of innovation in the pharmaceutical industry. J. Health Econ. 10 (2), 107-142.
2. Hartunian, N. et al., 1981. The incidence and economic costs of major health impairments. D.C. Heath, Lexington, MA.
3. Peltzman, S., 1973. An evaluation of consumer protection legislation: the 1962 drug amendments. J. Political Econ. 81 (5), 1049-1091.
4. Rimm, E. et al., 1993. Vitamin E consumption and the risk of coronary heart disease in men. New Engl. J. Med. 328 (20), 1450-1456.
5. Stampfer, M. et al., 1993. Vitamin E consumption and the risk of coronary disease in women. New Engl. J. Med. 328 (20), 1444-1449.
6. Thomas, L., 1975. The Lives of a Cell. Bantam Books, New York.
7. Viscusi, W.K., 1993. The value of risks to life and health. J. Econ. Literature 31 (4), 1912-1946.
8. Ward, M., Dranove, D., 1995. The vertical chain of medical research and development. Econ. Inquiry 33 (1), 70-87.
9. Weisbrod, B., 1991. The health care quadrilemma. J. Econ. Literature 29 (2), 523-552.